LABU241227P141000
- 0.00
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
How Is The Market Feeling About Alnylam Pharmaceuticals?
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Sarepta Awarded $115.2M in Vyondys 53 Patent Case: Report
Needham Reiterates Hold on Neurocrine Biosciencesto Hold
Gilead Sciences Acquires 7.85M Xilio Therapeutics Shares At $1.04 Each, Raising Ownership To Over 10%, Along With 6.1M Pre-Funded Warrants Capped At 19.99% Ownership
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
(GILD) - Analyzing Gilead Sciences's Short Interest
25 U.S. 'Highest Conviction' Stocks – UBS
Gilead Raises Assembly Bio Stake to ~30%
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target
Sarepta Therapeutics Analyst Ratings
Incyte Analyst Ratings
Gilead Gets FDA Breakthrough Therapy Status for Trodelvy
Gilead Sciences And Terray Therapeutics Have Entered Into A Strategic Collaboration To Discover And Develop Novel, Small Molecule Therapies Across Multiple Targets
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
Wolfe's Top 12 Shorted Stocks: FSLR, BE, WBA, and More